Q4 2025 electroCore, Inc. Earnings Call Transcript
Key Points
- electroCore Inc (ECOR) reported a record fourth-quarter revenue of $9.2 million, marking a 31% year-over-year increase.
- The company achieved a full-year 2025 revenue of $32 million, up 27% from 2024, driven by growth in both prescription and non-prescription products.
- The VA hospital system remains a significant growth driver, with 200 VA facilities purchasing gammaCore products, up from 170 the previous year.
- Truvaga sales showed strong growth, with a 93% increase in revenue from 2024, supported by e-commerce and affiliate networks.
- The company maintains a high gross margin of 87%, reflecting efficient operations and strong product demand.
- Net loss for 2025 increased to $14 million, compared to $11.9 million in 2024, primarily due to higher operating expenses.
- Selling, general, and administrative expenses rose by $7 million, driven by increased personnel and legal fees.
- The company faces challenges in expanding insurance reimbursement coverage, with Kaiser being a key focus for future growth.
- Return rates across e-commerce platforms have increased slightly, remaining at approximately 12% to 15%.
- Leadership transition may create uncertainty, as CEO Daniel Goldberger announced his retirement effective April 1, 2026.
You all for joining, we'll begin in about 30 seconds. Greetings, and welcome to the electroCore fourth quarter and full year 2025 earnings conference call. (Operator Instructions) Reminder, this con call is being recorded. Earlier today, electroCore published results for the fourth quarter and full year ended December 31, 2025.
A copy of the press release is available on the company's website. I'd like to remind you that members on the call will make statements during the call that include forward-looking statements within the meaning of the federal securities law, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that are not statements of historical fact should be deemed to be forward-looking.
All forward-looking statements, including without limitation, any guidance, outlook, or future financial expectation or operational activity and performance, including any statements regarding first quarter 2026 and full year performance and the path to profitability,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
